Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma

Eur J Nucl Med. 1988;14(7-8):349-51. doi: 10.1007/BF00254382.

Abstract

Forty-nine patients were treated with either 3 x 75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Bone Neoplasms / radiotherapy
  • Bone Neoplasms / secondary*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Palliative Care
  • Prognosis
  • Prostatic Neoplasms / radiotherapy*
  • Random Allocation
  • Strontium Radioisotopes / therapeutic use*

Substances

  • Strontium Radioisotopes